Hepcidin – Potential biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions.

MLA

Malyszko, Jolanta, et al. “Hepcidin – Potential Biomarker of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions.” Advances in Medical Sciences (Elsevier Inc.), vol. 64, no. 2, Sept. 2019, pp. 211–15. EBSCOhost, https://doi.org/10.1016/j.advms.2018.12.008.

APA

Malyszko, J., Bachorzewska-Gajewska, H., Malyszko, J. S., Koc-Zorawska, E., Matuszkiewicz-Rowinska, J., & Dobrzycki, S. (2019). Hepcidin – Potential biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions. Advances in Medical Sciences (Elsevier Inc.), 64(2), 211–215. https://doi.org/10.1016/j.advms.2018.12.008

Chicago

Malyszko, Jolanta, Hanna Bachorzewska-Gajewska, Jacek S. Malyszko, Ewa Koc-Zorawska, Joanna Matuszkiewicz-Rowinska, and Slawomir Dobrzycki. 2019. “Hepcidin – Potential Biomarker of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions.” Advances in Medical Sciences (Elsevier Inc.) 64 (2): 211–15. doi:10.1016/j.advms.2018.12.008.